Cargando…
PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429300/ http://dx.doi.org/10.1097/01.HS9.0000851336.89795.74 |
| _version_ | 1784779397897650176 |
|---|---|
| author | Lorenz, K. Strüßmann, T. Trepel, M. Illerhaus, G. Pelz, H. Scholz, C. Duyster, J. Marks, R. |
| author_facet | Lorenz, K. Strüßmann, T. Trepel, M. Illerhaus, G. Pelz, H. Scholz, C. Duyster, J. Marks, R. |
| author_sort | Lorenz, K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429300 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94293002022-08-31 PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY Lorenz, K. Strüßmann, T. Trepel, M. Illerhaus, G. Pelz, H. Scholz, C. Duyster, J. Marks, R. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429300/ http://dx.doi.org/10.1097/01.HS9.0000851336.89795.74 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Lorenz, K. Strüßmann, T. Trepel, M. Illerhaus, G. Pelz, H. Scholz, C. Duyster, J. Marks, R. PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_full | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_fullStr | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_full_unstemmed | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_short | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_sort | pb2126: r-cpop as first line treatment for dlbcl patients with significant reduced lvef or high risk of anthracycline induced cardiotoxicity |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429300/ http://dx.doi.org/10.1097/01.HS9.0000851336.89795.74 |
| work_keys_str_mv | AT lorenzk pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT strußmannt pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT trepelm pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT illerhausg pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT pelzh pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT scholzc pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT duysterj pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT marksr pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity |